These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1465 related items for PubMed ID: 23872058

  • 21. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR, Zwolak A, Williams JA, Chiu ML, Atkins WM.
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S, Cleiren E, Attar RM, Philippar U, Häsler J, Chiu ML.
    MAbs; 2019 May; 11(6):1012-1024. PubMed ID: 31242061
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.
    J Immunol Methods; 2011 Feb 28; 365(1-2):132-41. PubMed ID: 21185301
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Engineered Fc-glycosylation switch to eliminate antibody effector function.
    Zhou Q, Jaworski J, Zhou Y, Valente D, Cotton J, Honey D, Boudanova E, Beninga J, Rao E, Wei R, Mauriac C, Pan C, Park A, Qiu H.
    MAbs; 2020 Feb 28; 12(1):1814583. PubMed ID: 32892677
    [Abstract] [Full Text] [Related]

  • 35. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.
    MAbs; 2014 Feb 28; 6(5):1243-54. PubMed ID: 25517309
    [Abstract] [Full Text] [Related]

  • 36. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
    Arduin E, Arora S, Bamert PR, Kuiper T, Popp S, Geisse S, Grau R, Calzascia T, Zenke G, Kovarik J.
    Mol Immunol; 2015 Feb 28; 63(2):456-63. PubMed ID: 25451975
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
    Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N.
    Glycobiology; 2011 Aug 28; 21(8):1087-96. PubMed ID: 21470983
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D, Goldberg MV, Chiu ML.
    J Biol Chem; 2016 Dec 30; 291(53):27134-27146. PubMed ID: 27856634
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 74.